Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.
Identifieur interne : 001151 ( PubMed/Checkpoint ); précédent : 001150; suivant : 001152Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.
Auteurs : Darryl Falzarano [États-Unis] ; Emmie De Wit ; Cynthia Martellaro ; Julie Callison ; Vincent J. Munster ; Heinz FeldmannSource :
- Scientific reports [ 2045-2322 ] ; 2013.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Interféron alpha, Ribavirine.
- physiologie : Coronavirus, Réplication virale.
- Animaux, Association médicamenteuse, Cellules Vero, Coronavirus, Réplication virale.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Interferon-alpha, Ribavirin.
- chemical : Drug Combinations.
- drug effects : Coronavirus, Virus Replication.
- physiology : Coronavirus, Virus Replication.
- Animals, Chlorocebus aethiops, Vero Cells.
Abstract
The identification of a novel β coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-α2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-α2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.
DOI: 10.1038/srep01686
PubMed: 23594967
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23594967Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.</title><author><name sortKey="Falzarano, Darryl" sort="Falzarano, Darryl" uniqKey="Falzarano D" first="Darryl" last="Falzarano">Darryl Falzarano</name><affiliation wicri:level="2"><nlm:affiliation>Disease Modeling and Transmission Unit, Hamilton, MT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Disease Modeling and Transmission Unit, Hamilton, MT</wicri:regionArea><placeName><region type="state">Montana</region></placeName></affiliation></author><author><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name></author><author><name sortKey="Martellaro, Cynthia" sort="Martellaro, Cynthia" uniqKey="Martellaro C" first="Cynthia" last="Martellaro">Cynthia Martellaro</name></author><author><name sortKey="Callison, Julie" sort="Callison, Julie" uniqKey="Callison J" first="Julie" last="Callison">Julie Callison</name></author><author><name sortKey="Munster, Vincent J" sort="Munster, Vincent J" uniqKey="Munster V" first="Vincent J" last="Munster">Vincent J. Munster</name></author><author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23594967</idno><idno type="pmid">23594967</idno><idno type="doi">10.1038/srep01686</idno><idno type="wicri:Area/PubMed/Corpus">001215</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001215</idno><idno type="wicri:Area/PubMed/Curation">001215</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001215</idno><idno type="wicri:Area/PubMed/Checkpoint">001151</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.</title><author><name sortKey="Falzarano, Darryl" sort="Falzarano, Darryl" uniqKey="Falzarano D" first="Darryl" last="Falzarano">Darryl Falzarano</name><affiliation wicri:level="2"><nlm:affiliation>Disease Modeling and Transmission Unit, Hamilton, MT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Disease Modeling and Transmission Unit, Hamilton, MT</wicri:regionArea><placeName><region type="state">Montana</region></placeName></affiliation></author><author><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name></author><author><name sortKey="Martellaro, Cynthia" sort="Martellaro, Cynthia" uniqKey="Martellaro C" first="Cynthia" last="Martellaro">Cynthia Martellaro</name></author><author><name sortKey="Callison, Julie" sort="Callison, Julie" uniqKey="Callison J" first="Julie" last="Callison">Julie Callison</name></author><author><name sortKey="Munster, Vincent J" sort="Munster, Vincent J" uniqKey="Munster V" first="Vincent J" last="Munster">Vincent J. Munster</name></author><author><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name></author></analytic><series><title level="j">Scientific reports</title><idno type="eISSN">2045-2322</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Coronavirus (drug effects)</term><term>Coronavirus (physiology)</term><term>Drug Combinations</term><term>Interferon-alpha (administration & dosage)</term><term>Ribavirin (administration & dosage)</term><term>Vero Cells</term><term>Virus Replication (drug effects)</term><term>Virus Replication (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Association médicamenteuse</term><term>Cellules Vero</term><term>Coronavirus ()</term><term>Coronavirus (physiologie)</term><term>Interféron alpha (administration et posologie)</term><term>Ribavirine (administration et posologie)</term><term>Réplication virale ()</term><term>Réplication virale (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Interferon-alpha</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Interféron alpha</term><term>Ribavirine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus</term><term>Réplication virale</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Coronavirus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Association médicamenteuse</term><term>Cellules Vero</term><term>Coronavirus</term><term>Réplication virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The identification of a novel β coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-α2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-α2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23594967</PMID><DateCompleted><Year>2013</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.</ArticleTitle><Pagination><MedlinePgn>1686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep01686</ELocationID><Abstract><AbstractText>The identification of a novel β coronavirus, nCoV, as the causative agent of severe respiratory illness in humans originating in Saudi Arabia, Qatar and Jordan has raised concerns about the possibility of a coronavirus pandemic similar to that of SARS-CoV. As a definitive treatment regimen has never been thoroughly evaluated for coronavirus infections, there is an urgent need to rapidly identify potential therapeutics to address future cases of nCoV. To determine an intervention strategy, the effect of interferon-α2b and ribavirin on nCoV isolate hCoV-EMC/2012 replication in Vero and LLC-MK2 cells was evaluated. hCoV-EMC/2012 was sensitive to both interferon-α2b and ribavirin alone in Vero and LLC-MK2 cells, but only at relatively high concentrations; however, when combined, lower concentrations of interferon-α2b and ribavirin achieved comparable endpoints. Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Falzarano</LastName><ForeName>Darryl</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Disease Modeling and Transmission Unit, Hamilton, MT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Wit</LastName><ForeName>Emmie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Martellaro</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Callison</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Munster</LastName><ForeName>Vincent J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Feldmann</LastName><ForeName>Heinz</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId><ArticleId IdType="pii">srep01686</ArticleId><ArticleId IdType="doi">10.1038/srep01686</ArticleId><ArticleId IdType="pmc">PMC3629412</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2005 Mar;5(3):147-55</Citation><ArticleIdList><ArticleId IdType="pubmed">15766649</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Jan 28;326(4):905-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15607755</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2005 Jun;66(2-3):159-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15911031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Feb;81(4):1574-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17121802</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2008 Jun 20;371(1):110-3</Citation><ArticleIdList><ArticleId IdType="pubmed">18406349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2008 Sep;62(3):437-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18565970</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Chem Chemother. 2010;20(4):169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20231782</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2010;5(6):e11265</Citation><ArticleIdList><ArticleId IdType="pubmed">20582319</ArticleId></ArticleIdList></Reference><Reference><Citation>Antivir Ther. 2010;15(5):687-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20710050</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 Dec 15;51(12):1435-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21058912</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2011 Jan;89(1):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21093489</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2011 Dec;1(6):590-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22440916</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2012 Aug;56(8):4168-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22615273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Sep;12(9):717-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22647717</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2012;17(39). pii: 20285</Citation><ArticleIdList><ArticleId IdType="pubmed">23041020</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012;3(6). pii: e00473-12. doi: 10.1128/mBio.00473-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012;3(6). pii: e00515-12. doi: 10.1128/mBio.00515-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23232719</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2013;4(1):e00548-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23300251</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;346:f1030</Citation><ArticleIdList><ArticleId IdType="pubmed">23412740</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2013;346:f1133</Citation><ArticleIdList><ArticleId IdType="pubmed">23423508</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013;18(8). pii: 20406</Citation><ArticleIdList><ArticleId IdType="pubmed">23449231</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2013;18(11):20427</Citation><ArticleIdList><ArticleId IdType="pubmed">23517868</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference><Reference><Citation>Nephron. 2002 Aug;91(4):627-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12138265</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2003 May 13;168(10):1289-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12743076</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1986-94</Citation><ArticleIdList><ArticleId IdType="pubmed">12682352</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Jul 26;362(9380):293-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12892961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Mar;10(3):290-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14981511</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 Feb;10(2):317-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15030704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Apr 1;189(7):1164-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15031783</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Investig Drugs. 2004 Feb;5(2):179-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15043392</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Interferon Cytokine Res. 2004 Jul;24(7):388-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15296649</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2004 Nov 10;329(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15476870</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Microbiol. 1989 Jul;20(3):255-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2549687</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1990 Nov;19(5):390-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1702693</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2005 Jun;66(2-3):99-102</Citation><ArticleIdList><ArticleId IdType="pubmed">15911026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Montana</li></region></list><tree><noCountry><name sortKey="Callison, Julie" sort="Callison, Julie" uniqKey="Callison J" first="Julie" last="Callison">Julie Callison</name><name sortKey="De Wit, Emmie" sort="De Wit, Emmie" uniqKey="De Wit E" first="Emmie" last="De Wit">Emmie De Wit</name><name sortKey="Feldmann, Heinz" sort="Feldmann, Heinz" uniqKey="Feldmann H" first="Heinz" last="Feldmann">Heinz Feldmann</name><name sortKey="Martellaro, Cynthia" sort="Martellaro, Cynthia" uniqKey="Martellaro C" first="Cynthia" last="Martellaro">Cynthia Martellaro</name><name sortKey="Munster, Vincent J" sort="Munster, Vincent J" uniqKey="Munster V" first="Vincent J" last="Munster">Vincent J. Munster</name></noCountry><country name="États-Unis"><region name="Montana"><name sortKey="Falzarano, Darryl" sort="Falzarano, Darryl" uniqKey="Falzarano D" first="Darryl" last="Falzarano">Darryl Falzarano</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23594967
|texte= Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23594967" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |